Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.
Suwaidi
Jassim Al
JA
Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Doha, State of Qatar. jha01@hmc.org.qa
Salam
Amar M
AM